Comparative Pharmacology
Head-to-head clinical analysis: MAGNACORT versus OTOBIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNACORT versus OTOBIOTIC.
MAGNACORT vs OTOBIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Otobiotic is a fixed-dose combination of ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial DNA replication inhibition and cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and reducing inflammatory mediators.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
Adults and children: 3-4 drops into the affected ear twice daily for 7 days. Shake well before use.
None Documented
None Documented
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Terminal elimination half-life: 2-3 hours in patients with normal renal function; prolonged to 24-48 hours in anuria.
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Renal elimination of unchanged drug: 60-80%; biliary/fecal elimination: 10-20%; the remainder undergoes hepatic metabolism.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid